<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173106</url>
  </required_header>
  <id_info>
    <org_study_id>Usix-IMN-001</org_study_id>
    <nct_id>NCT02173106</nct_id>
  </id_info>
  <brief_title>A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy</brief_title>
  <official_title>Opportunity, Validity and Security of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, randomized, controlled, multicenter clinical trial will evaluate
      Opportunity, Validity and Security of Steroids Plus Cyclosporin therapy for patients of
      Idiopathic Membranous Nephropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic membranous nephropathy is a main reason for nephropathy. Since it can get
      spontaneous remission, in KDIGO, it is recommend that initial therapy should be started only
      in patients with nephrotic syndrome and when at least the following condition is met:urinary
      protein excretion persistently exceeds 4g/d and remains at over 50% of the baseline value,and
      does not show progressive and antiproteinuric therapy during an observation period of at
      least 6 months. But many retrospective researches reported that using steroids and
      immunosuppressive agents were better than waiting for spontaneous remission. There were few
      prospective, randomized, controlled research on whether it is better that begin to use
      steroids and immunosuppressive agent early without waiting for 6 months. In our study,we
      evaluate the validity and security of steroids plus cyclosporin therapy in idiopathic
      membranous nephropathy. This will be a prospective, randomized, controlled, multicenter
      study. Patients in treatment group will receive oral methylprednisolone 0.4mg/kg/d and
      3.5~5mg/kg/d cyclosporin for 6 months. Patients in control group will waiting for spontaneous
      remission for 6 months,if there were no spontaneous remissions, patients in control group
      will receive oral methylprednisolone 0.4mg/kg/d and 3.5~5mg/kg/d cyclosporin for 6 months.
      After followed-up for 6 months the curative and side effect of steroid plus cyclosporin
      therapy in the early stage of idiopathic membranous nephropathy will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission of proteinuria (complete or partial)</measure>
    <time_frame>up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deterioration of renal function (evidenced by a 50% rise from baseline serum creatinine (SCr) levels, or a 25% decline from baseline eGFR levels, or onset of end-stage renal disease or dialysis treatment, or kidney transplantation).</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Idiopathic Membranous Nephropathy</condition>
  <condition>Proteinuria</condition>
  <condition>Spontaneous Remission</condition>
  <condition>Steroid Nephropathy</condition>
  <condition>Cyclosporin Overdose</condition>
  <arm_group>
    <arm_group_label>Group A: steroid &amp; Cyclosporin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral methylprednisolone 0.4mg/kg/d and 3.5~5mg/kg/d cyclosporin for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: no steroid &amp; Cyclosporin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no steroid and cyclosporin and waiting for spontaneous remission for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>steroid &amp; Cyclosporin</intervention_name>
    <description>oral methylprednisolone 0.4mg/kg/d and Cyclosporin for 6 months</description>
    <arm_group_label>Group A: steroid &amp; Cyclosporin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 14~75 years, regardless of gender without secondary reason, idiopathic membranous
             nephropathy by renal biopsy

          -  Average urinary protein excretion of at least3.5g/24h on two successive
             examinations,or plasma albumin &lt;30g/l

          -  eGFR≥40ml/min/1.73m2

          -  Willingness to sign an informed consent

        Exclusion Criteria:

          -  Secondary membranous nephropathy such as systemic lupus erythematosus, hepatitis B
             -associated nephritis

          -  Current or recent (within 30 days) exposure to high-dose of steroids or
             immunosuppressive therapy (CTX、MMF、CsA、FK506).

          -  Cirrhosis, chronic active liver disease

          -  History of significant gastrointestinal disorders (e.g. severe chronic diarrhea or
             active peptic ulcer disease)

          -  Any Active systemic infection or history of serious infection within one month.

          -  Other major organ system disease (e.g. serious cardiovascular diseases including
             congestive heart failure, chronic obstructive pulmonary disease, asthma requiring oral
             steroid treatment or central nervous system diseases)

          -  Active tuberculosis

          -  Known allergy, contraindication or intolerance to the steroids

          -  Pregnancy or breast feeding at the time of entry or unwillingness to comply with
             measures for contraception

          -  Malignant tumors

          -  Excessive drinking or drug abuse

          -  Mental aberrations

          -  Current or recent (within 30 days) exposure to any other investigational drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zongpei Jiang, MD &amp;Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Sixth Affiliated Hospital,Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zongpei Jiang, MD&amp;Ph D</last_name>
    <phone>8620-38379727</phone>
    <email>jx.home@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Nephrology,Dongguan People's Hospital</name>
      <address>
        <city>Dongguan</city>
        <state>Guangdong</state>
        <zip>523059</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guohui Liu, MD</last_name>
      <phone>86769-28637333</phone>
      <email>liuguohui5@126.com</email>
    </contact>
    <investigator>
      <last_name>Guohui Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology, 2nd Affiliated Hospital,Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianbo Liang, MD.</last_name>
      <phone>8620-34152282</phone>
      <email>boliangjian@tom.com</email>
    </contact>
    <investigator>
      <last_name>Jianbo Liang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology, 6th Affiliated Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zongpei Jiang, MD &amp; Ph. D</last_name>
      <phone>8620-38379727</phone>
      <email>jx.home@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Zongpei Jiang, MD &amp; Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology,Huizhou Municipal Central Hospital</name>
      <address>
        <city>Huizhou</city>
        <state>Guangdong</state>
        <zip>516001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiqiang Zhong, MD</last_name>
      <phone>86752—2288288</phone>
      <email>13809669766@126.com</email>
    </contact>
    <investigator>
      <last_name>Weiqiang Zhong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology,1st Affiliated Hospital,Shenzhen University</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongcheng He, MD</last_name>
      <phone>86755-83366388</phone>
      <email>heyongcheng@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yongcheng He, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology,1st People's Hospital of Zhaoqing</name>
      <address>
        <city>Zhaoqing</city>
        <state>Guangdong</state>
        <zip>526020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinquan Wu, MD</last_name>
      <phone>86758-2832139</phone>
      <email>zqwujq@163.com</email>
    </contact>
    <investigator>
      <last_name>Jinquan Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 30, 2014</last_update_submitted>
  <last_update_submitted_qc>June 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yanhong Deng</investigator_full_name>
    <investigator_title>The Sixth Affiliated Hospital of Sun Yat-Sen University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
    <mesh_term>Remission, Spontaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

